US Penny Stocks To Consider In October 2024

Major U.S. stock indexes have seen a downturn recently, with the Dow Jones, S&P 500, and Nasdaq Composite all experiencing declines amid rising Treasury yields and mixed earnings reports. Despite these fluctuations, there remains potential in the market for those willing to explore beyond established giants. Penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at attractive price points when backed by strong fundamentals and solid balance sheets.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.786075	$5.8M	★★★★★★
RLX Technology (NYSE:RLX)	$1.63	$2.06B	★★★★★★
LexinFintech Holdings (NasdaqGS:LX)	$3.33	$517.9M	★★★★★★
ARC Document Solutions (NYSE:ARC)	$3.42	$147.91M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.57	$51.81M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.21	$8.33M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$3.75	$114.35M	★★★★★★
MIND C.T.I (NasdaqGM:MNDO)	$1.88	$39.56M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$1.07	$98.03M	★★★★★☆

Click here to see the full list of 755 stocks from our US Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Marker Therapeutics (NasdaqCM:MRKR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing novel T cell-based immunotherapies for treating hematological malignancies and solid tumors, with a market cap of $33.01 million.

Operations: The company's revenue is derived from its biotechnology startups segment, totaling $3.73 million.

Market Cap: $33.01M

Marker Therapeutics is navigating the challenging landscape of penny stocks with a focus on T cell-based immunotherapies. Recent earnings showed a revenue increase to US$1.17 million for Q2 2024, though the company remains unprofitable with a net loss of US$2.19 million. Despite financial hurdles, Marker secured a significant US$2 million NIH grant to advance its MT-601 therapy for non-Hodgkin’s lymphoma, underscoring potential in its clinical pipeline. The company has no debt and manageable short-term liabilities but faces concerns over cash runway and profitability forecasts, making it a high-risk investment with speculative appeal in biotechnology advancements.

• Get an in-depth perspective on Marker Therapeutics' performance by reading our balance sheet health report here.
• Gain insights into Marker Therapeutics' future direction by reviewing our growth report.

PMV Pharmaceuticals (NasdaqGS:PMVP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule and tumor-agnostic therapies targeting p53 mutations in cancer, with a market cap of $81.92 million.

Operations: PMV Pharmaceuticals, Inc. does not report any revenue segments.

Market Cap: $81.92M

PMV Pharmaceuticals is a pre-revenue company in the precision oncology sector, with a market cap of US$81.92 million. Despite being unprofitable and experiencing shareholder dilution, it maintains strong short-term assets of US$218.8 million that cover both its short and long-term liabilities. The management and board are experienced, with average tenures over three years. Recent strategic moves include terminating a costly lease to reduce expenses, although earnings are forecasted to decline by 2% annually over the next three years. Analysts predict significant stock price appreciation potential despite current challenges in achieving profitability.

• Click here to discover the nuances of PMV Pharmaceuticals with our detailed analytical financial health report.
• Examine PMV Pharmaceuticals' earnings growth report to understand how analysts expect it to perform.

Yalla Group (NYSE:YALA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Yalla Group Limited operates a social networking and gaming platform primarily in the Middle East and North Africa region, with a market cap of $667.25 million.

Operations: The company generates $326.04 million in revenue from its social networking and entertainment platform.

Market Cap: $667.25M

Yalla Group, with a market cap of US$667.25 million, has demonstrated robust financial health and growth within the social networking and gaming sectors. The company reported significant revenue of US$326.04 million, with earnings for the second quarter reaching US$81.2 million, reflecting an increase from the previous year. Yalla's earnings growth rate exceeds industry averages and remains debt-free, enhancing its financial stability. Its short-term assets significantly surpass liabilities, ensuring liquidity strength. Despite stable weekly volatility and no shareholder dilution over the past year, Yalla trades at a substantial discount to its estimated fair value, presenting potential investment appeal in penny stock discussions.

• Click here and access our complete financial health analysis report to understand the dynamics of Yalla Group.
• Assess Yalla Group's future earnings estimates with our detailed growth reports.

Next Steps

• Reveal the 755 hidden gems among our US Penny Stocks screener with a single click here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com